BR9506612A - Processo para produzir uma proteina de região V de receptor de antigeno de célula T de comprimento completo recombinante vetor de express o célula bacteriana proteina de região V de receptor de antigeno de célula T de comprimento completo composição farmacêutica processo para tratar um distúrbio relacionado com a imunidade proteina VB5.3 de receptor de antigeno de célula T substancialmente pura uso de uma proteina célula bacteriana transformada e processo para diagnosticar um distúrbio da imunidade - Google Patents

Processo para produzir uma proteina de região V de receptor de antigeno de célula T de comprimento completo recombinante vetor de express o célula bacteriana proteina de região V de receptor de antigeno de célula T de comprimento completo composição farmacêutica processo para tratar um distúrbio relacionado com a imunidade proteina VB5.3 de receptor de antigeno de célula T substancialmente pura uso de uma proteina célula bacteriana transformada e processo para diagnosticar um distúrbio da imunidade

Info

Publication number
BR9506612A
BR9506612A BR9506612A BR9506612A BR9506612A BR 9506612 A BR9506612 A BR 9506612A BR 9506612 A BR9506612 A BR 9506612A BR 9506612 A BR9506612 A BR 9506612A BR 9506612 A BR9506612 A BR 9506612A
Authority
BR
Brazil
Prior art keywords
antigen receptor
protein
cell antigen
immunity
full length
Prior art date
Application number
BR9506612A
Other languages
English (en)
Inventor
Savvas C Makrides
Patrick C Kung
Original Assignee
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc filed Critical T Cell Sciences Inc
Publication of BR9506612A publication Critical patent/BR9506612A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
BR9506612A 1994-01-13 1995-01-12 Processo para produzir uma proteina de região V de receptor de antigeno de célula T de comprimento completo recombinante vetor de express o célula bacteriana proteina de região V de receptor de antigeno de célula T de comprimento completo composição farmacêutica processo para tratar um distúrbio relacionado com a imunidade proteina VB5.3 de receptor de antigeno de célula T substancialmente pura uso de uma proteina célula bacteriana transformada e processo para diagnosticar um distúrbio da imunidade BR9506612A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/181,492 US5552300A (en) 1994-01-13 1994-01-13 T cell antigen receptor V region proteins and methods of preparation thereof
PCT/US1995/000408 WO1995019435A2 (en) 1994-01-13 1995-01-12 T cell antigen receptor v region proteins and methods of preparation thereof

Publications (1)

Publication Number Publication Date
BR9506612A true BR9506612A (pt) 1997-09-16

Family

ID=22664497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9506612A BR9506612A (pt) 1994-01-13 1995-01-12 Processo para produzir uma proteina de região V de receptor de antigeno de célula T de comprimento completo recombinante vetor de express o célula bacteriana proteina de região V de receptor de antigeno de célula T de comprimento completo composição farmacêutica processo para tratar um distúrbio relacionado com a imunidade proteina VB5.3 de receptor de antigeno de célula T substancialmente pura uso de uma proteina célula bacteriana transformada e processo para diagnosticar um distúrbio da imunidade

Country Status (21)

Country Link
US (1) US5552300A (pt)
EP (1) EP0738322A1 (pt)
JP (1) JPH10501961A (pt)
KR (1) KR100213396B1 (pt)
AU (1) AU700661B2 (pt)
BR (1) BR9506612A (pt)
CA (1) CA2181171A1 (pt)
CZ (1) CZ9602009A3 (pt)
EE (1) EE03287B1 (pt)
FI (1) FI962844A (pt)
HU (1) HUT75551A (pt)
IL (1) IL112316A0 (pt)
LV (1) LV11630B (pt)
MX (1) MX9602750A (pt)
NO (1) NO962921L (pt)
NZ (2) NZ279605A (pt)
PL (1) PL181072B1 (pt)
SG (1) SG52342A1 (pt)
SK (1) SK90696A3 (pt)
WO (1) WO1995019435A2 (pt)
ZA (1) ZA95261B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20040229282A1 (en) * 1997-03-10 2004-11-18 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
EP1165132B1 (en) 1999-04-08 2011-10-19 Intercell USA, Inc. Dry formulation for transcutaneous immunization
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
ES2545736T3 (es) * 2002-08-08 2015-09-15 Baylor College Of Medicine Aislamiento e identificación de células T
MXPA05013789A (es) * 2003-06-19 2006-06-27 Tanox Inc Composiciones y metodos para tratar los desordenes relacionados con la coagulacion.
EP1768742A4 (en) * 2004-07-06 2007-10-17 Transpharma Medical Ltd ADMINISTRATION SYSTEM FOR TRANSDERMAL IMMUNIZATION
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
US20070009542A1 (en) 2005-07-05 2007-01-11 Galit Levin Method and device for transdermal immunization
CA2620943A1 (en) 2005-09-02 2007-03-08 Iomai Corporation Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof
DK2016414T3 (en) * 2006-05-05 2015-12-07 Opexa Therapeutics T-cell vaccine
US8606366B2 (en) 2009-02-18 2013-12-10 Syneron Medical Ltd. Skin treatment apparatus for personal use and method for using same
US9968666B2 (en) 2009-06-12 2018-05-15 Vaccine Technologies, Incorporated Methods and compositions for promoting a cell-mediated immune response
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713332A (en) * 1984-01-13 1987-12-15 The Ontario Cancer Institute T cell specific CDNA clone
WO1985003947A1 (en) * 1984-03-01 1985-09-12 The Board Of Trustees Of The Leland Stanford Jr. U T-cell receptor-specific for antigen polypeptides and related polynucleotides
US4873190A (en) * 1984-06-13 1989-10-10 Massachusetts Institute Of Technology Heterodimeric T lymphocyte receptor
US4845026A (en) * 1985-12-03 1989-07-04 T Cell Sciences, Inc. Assay systems for detecting cell-free T cell antigen receptor related molecules and the clinical utilities of the assays
US5185250A (en) * 1986-07-03 1993-02-09 T Cell Sciences, Inc. Human γ, δT cell antigen receptor polypeptides and nucleic acids
US5024940A (en) * 1987-02-19 1991-06-18 T Cell Sciences, Inc. Nucleic acids encoding the delta chain of the T cell antigen receptor
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection
ES2093606T3 (es) * 1987-06-23 1997-01-01 Univ Leland Stanford Junior Gen del receptor de celulas t localizado en el locus alfa y estructuras artificiales de adn.
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
ES2062519T5 (es) * 1989-03-21 2003-07-16 Immune Response Corp Inc Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t.
CA2032138A1 (en) * 1989-05-02 1990-11-03 Irun R. Cohen Anti-ergotypic t cells for the treatment or prevention of autoimmune diseases and methods of use thereof
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
ATE140733T1 (de) * 1990-05-01 1996-08-15 Univ Leland Stanford Junior Stoffgemische zur anwendung in einem verfahren zur behandlung eines an multipler sklerose leidenden menschen
ES2098368T3 (es) * 1990-08-09 1997-05-01 Nat Jewish Ct Immun & Respirat Produccion de anticuerpos monoclonales contra un elemento vbeta humano de los receptores de las celulas t, utilizando vectores de adn recombinante.
EP0528007A1 (fr) * 1991-02-12 1993-02-24 Roussel Uclaf SEQUENCES NUCLEOTIDIQUES CODANT POUR DES REGIONS VARIABLES DE CHAINES $g(b) DES RECEPTEURS DES LYMPHOCYTES T HUMAINS, SEGMENTS PEPTIDIQUES CORRESPONDANTS ET LES APPLICATIONS DIAGNOSTIQUES ET THERAPEUTIQUES
ES2144418T3 (es) * 1991-05-31 2000-06-16 Connetics Corp Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
JPH06511241A (ja) * 1991-09-23 1994-12-15 ジェネンテク，インコーポレイテッド 自己免疫疾患の診断および治療
US5333487A (en) * 1991-11-15 1994-08-02 Hughes Aircraft Company Spark-excited fluorescence sensor
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor

Also Published As

Publication number Publication date
AU1678495A (en) 1995-08-01
AU700661B2 (en) 1999-01-14
CZ9602009A3 (en) 1997-12-17
HUT75551A (en) 1997-05-28
SK90696A3 (en) 1997-07-09
FI962844A0 (fi) 1996-07-12
PL181072B1 (pl) 2001-05-31
NO962921D0 (no) 1996-07-11
NZ332715A (en) 2000-06-23
HU9601908D0 (en) 1996-09-30
LV11630A (lv) 1996-12-20
CA2181171A1 (en) 1995-07-20
KR970700772A (ko) 1997-02-12
NZ279605A (en) 1999-01-28
WO1995019435A2 (en) 1995-07-20
EP0738322A1 (en) 1996-10-23
JPH10501961A (ja) 1998-02-24
MX9602750A (es) 1997-05-31
IL112316A0 (en) 1995-03-30
SG52342A1 (en) 1999-06-22
KR100213396B1 (ko) 1999-08-02
NO962921L (no) 1996-09-02
US5552300A (en) 1996-09-03
FI962844A (fi) 1996-08-29
ZA95261B (en) 1995-11-14
WO1995019435A3 (en) 1995-08-24
LV11630B (en) 1997-08-20
EE03287B1 (et) 2000-08-15
PL319374A1 (en) 1997-08-04

Similar Documents

Publication Publication Date Title
BR9506612A (pt) Processo para produzir uma proteina de região V de receptor de antigeno de célula T de comprimento completo recombinante vetor de express o célula bacteriana proteina de região V de receptor de antigeno de célula T de comprimento completo composição farmacêutica processo para tratar um distúrbio relacionado com a imunidade proteina VB5.3 de receptor de antigeno de célula T substancialmente pura uso de uma proteina célula bacteriana transformada e processo para diagnosticar um distúrbio da imunidade
EP1958965A3 (en) Agonist antibodies to a musk receptor, and their therapeutic uses
MX9707021A (es) Receptor de il-7.
EP0880597A4 (en) THERAPEUTIC APPLICATIONS FOR MONOCLONAL ANTIBODY 5c8 ANTI-T-BAM (ANTI-CD40-L)
BR9607012A (pt) Processo para gerar uma imagem de corpo de animal humano por formação de imagem luminosa uso de uma material em partículas fisiologicamente toleráveis e composição de formação de imagem diagnóstica
IL116816A (en) Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE69829617D1 (de) Tonerzuführbehälter und Bilderzeugungsgerät, das diesen Behälter verwendet
DE69029327D1 (de) Neue antikörper reaktiv gegen menschliche karzinome
HUP9904177A3 (en) Antibody against human parathormone related peptides
DE69623778D1 (de) Anschwellendes bahnmaterial mit glasfasern
DE69428871D1 (de) Aufzeichnungsmaterial und Bildaufzeichnungsverfahren, das dieses Material benutzt
AU6916296A (en) Recombinant anti-cd4 antibodies for human therapy
BR9609299A (pt) Derivados de &-hordotionina com elevado teor de metionina
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
PL336470A1 (en) Mammalian cytokin-like factor 7
ATA33697A (de) Faktor x-deletionsmutanten und analoge davon
DE69507764D1 (de) Aufzeichnungsmaterial und Bildaufzeichnungsverfahren, das dieses Material verwendet
DE69428763D1 (de) Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
BR9507451A (pt) Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo
DE69500575D1 (de) Neue Sonnenschutzfilter, diese enthaltende kosmetische Sonnenschutzmittel und deren Verwendungen
EE03783B1 (et) Farmatseutiline kompositsioon epitelioomide raviks ja antikeha või antikeha molekuli kasutamine
HUP9602570A2 (en) Process for producing immunoglobulines from fractions produced with fractioning human blood-plasma
SE9501067D0 (sv) New peptides
IL116228A0 (en) Monoclonal antibody fragments and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PC Transfer

Free format text: ASTRA AB (SE)

TE Change of address
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal